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ABSTRACT
Objective: Nanostructured lipid carrier (NLC)-based topical gel of lornoxicam (LXM) was formulated with the aim of controlled release action and to 
reduce systemic side effect for the treatment of an arthritic condition.
Methods: NLCs developed using high-pressure homogenization method and optimized using a 32 factorial design with response surface methodology 
using design expert software. NLCs were characterized for particle size, zeta potential analysis, drug entrapment efficiency, and in vitro drug release 
studies to select the optimized formulation. The NLCs were suitably gelled and evaluated with respect to homogeneity, pH, viscosity, gel strength, 
spreadability, rheological characteristics, drug content, in vitro diffusion, and stability study. Safety of the NLC-based gel was assessed using primary 
skin irritation studies, and efficacy was confirmed using carrageenan-induced rat paw edema model.
Results: NLCs formulation comprising 2% of lipid (60:40) and surfactant (1.50%) was confirmed as an optimized batch having a particle size 
(138.2±3.60 nm) with polydispersibility index value 0.344±0.034. The zeta potential value indicates good physical stability. Based on the results from 
the in vitro release study it was shown that the formed gels had the ability to extend release of LXM for 24 h and showing percentage drug release 
of 90.92%±1.96% at the end of 24 h. Skin irritation studies revealed that the optimized gel formulation shows no erythema, edema, or ulceration.
Conclusion: The overall results of the present study clearly indicated promising potentials of NLC-based gel for delivering LXM topically over the 
conventional gel.
Keywords: Nanolipid carrier, Lornoxicam, Response surface methodology, Topical gel.
INTRODUCTION
In the past decade, solid lipid nanoparticles (SLN) and nanostructured 
lipid carriers (NLC) have been looked on as promising carriers for 
presenting several attractive features for transdermal drug delivery [1]. 
These carriers are composed of physiological and biodegradable lipids 
exhibiting low systemic toxicity and low cytotoxicity. The small size 
of the lipid particles ensures close contact with stratum corneum 
and can increase the amount of drug penetrating into mucosa or 
skin. Due to their solid lipid matrix, a controlled release from these 
carriers is possible [1,2]. This becomes an important tool when it 
is necessary to supply the drug over a prolonged period of time, to 
reduce systemic absorption, and when drug produces irritation in 
high concentrations. To overcome some of the limitations of SLNs, 
namely limited drug loading and drug leakage during storage, NLCs 
have been developed [3,4]. They consist of a solid lipid matrix with a 
high content of liquid lipid. NLCs were studied and introduced with 
an intention to overcome the limitations of SLNs such as limited drug 
loading and drug leakage during storage. NLCs are the new generation 
of lipid nanoparticles, attracting major attention as novel colloidal drug 
carriers for topical use [4,5].
Lornoxicam (LXM) is a nonsteroidal anti-inflammatory drug (NSAID) 
belonging to an oxicam class having potent analgesic and anti-
inflammatory effects. The mechanism of action of LXM, like that of other 
NSAIDs, is mainly due to the inhibition of prostaglandin biosynthesis 
through the inhibition of the cyclooxygenase (COX) enzymes COX-l and 
COX-2 [6]. It is recommended widely for symptomatic treatment of pain 
and inflammation linked with rheumatoid arthritis, osteoarthritis and 
proven to have efficacy in the management of pre-operative and post-
operative pain associated with abdominal, bone-related, gynecological, 
and dental surgeries [7,8]. It requires repeated oral administration is 
due to to its short duration of action and low elimination half-life. The 
major well-known side effects of all NSAIDs are gastric irritation and 
peptic ulcers [8].
Hence, in the present investigation, the feasibility of NLC as a novel 
carrier system for topical application of LXM, with regard to the 
prolong of the release and bypass the hepatic first-pass effect was 
checked. Thus, the possibility of delivering LXM through the skin for 
local inflammation at low doses is beneficial. The role played by the oily 
phase component of the NLC was also judged by comparing the in vitro 
release. To increase the therapeutic efficacy of topically applied drugs, 
LXM-NLCs were incorporated within the gel matrix which was expected 
to deliver the drug for the extended period of time.
MATERIALS AND METHODS
Materials
LXM was obtained as a gift sample from Alkem Laboratories Ltd., Mumbai. 
Precirol ATO 5 was gifted from Gattefosse India Pvt., Ltd., Pluronic F-68 
was gift sample by BASF ChemTrade GmbH (Burgbernheim, Germany)., 
Oleic acid by Loba Chemie, Mumbai, Carbopol-940 was procured from 
HiMedia Lab, Mumbai. Other required chemicals were of analytical 
grade procured from S.D Fine Chemicals, Mumbai, India.
Animals
Albino Wistar rats were used after obtaining the due permission 
for conducting in vivo studies, from Institutional Ethics Committee 
(Dadasaheb Balpande College of Pharmacy, Nagpur, India). The protocol 
according to form B was approved by Committee for the Purpose of 
Control and Supervision of Experiments on Animals (CPCSEA) and 
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i4.32000
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Institutional Animal Ethics Committee (Registration number 1426/PO/
Re/S/11/CPCSEA).
Screening of lipid
Before the formulation of NLC’s, screening of components should be 
performed to determine the most suitable solid lipid and liquid lipid 
that could be used in the preparation of NLCs, to give high entrapment 
of the drug and maximum drug loading into the lipid matrix. For this 
purpose, the solubility of LXM was determined in different solid lipids, 
oils, and surfactants. The solubility in solid lipids, i.e., stearic acid, 
compritol 888, and Precirol ATO5(1000 mg) was taken in each test tube, 
the weighed amount of drug was added into the test tubes which were 
heated in a controlled temperature water bath kept at 80°C. The drug 
was added until the saturation was achieved. The remaining amount of 
the drug was weighed again, and by that way, the quantity required to 
dissolve drug was found out [7-9].
Design for optimizing formulations
To obtain the optimal formulations with appropriate drug 
encapsulation efficiency and mean particle size of LXM-NLC, a 32 
factorial design based on a response surface methodology (RSM) was 
used to evaluate the effects of lipid concentration (X1) and surfactant 
concentration (X2). Objectives of this study were to establish the 
functional relationships between two operating variables of solid 
lipid concentration (X1) and surfactant concentration (X2) and two 
responses of encapsulation efficiency and mean particle size of NLC, 
respectively. To optimize LXM-NLC, mathematical model equations were 
derived by computer simulation programming Design-Expert® 8.0.1. 
For a better understanding of the two variables for the optimal LXM-
NLC performance, the models were presented as three-dimensional 
(3D) response surface graphs [7,8]. To carry out the above-mentioned 
study, for each factor (operating variable), the experimental range was 
selected on the basis of the results of preliminary experiments and 
the feasibility of preparing the NLC at the extreme values as shown in 
Table 1.
Drug-excipients interaction study
The drug-excipients interaction study was carried out using Fourier-
transform infrared (FT-IR) and differential scanning calorimetry (DSC). 
FTIR spectra of LXM, Precirol ATO-5 (PRE) and physical mixture of 
lipids with LXM were studied using FTIR spectrophotometer (Shimadzu 
8400S, Japan) at 10–12 tones pressure and thermal analysis was carried 
out using DSC (Mettler DSC 1 star system, Mettler-Toledo, Switzerland) 
at a heating rate of 10°C/min. The measurements were performed at a 
heating range of 40–300°C under nitrogen atmospheres [9].
Method of preparation of NLC’s
The NLC was prepared by a modified method of hot high-pressure 
homogenization technique. LXM was dispersed in the lipid phase 
(consisted of Precirol ATO-5 and Oleic acid in 60:40 ratio) and kept 
in a heating water bath at 80°C [10]. The aqueous phase comprised 
surfactant (poloxamer188) dissolved in water. Both the phases were 
maintained at a temperature above the melting point of the lipid (80°C). 
At this temperature, the melted hot lipid phase was then dispersed in 
the hot surfactant phase obtaining a pre-emulsion under mechanical 
stirring (Remi Instruments Ltd., Mumbai, India) at 800 rpm at 80°C for 
30 min.
The warm pre-emulsion was introduced into a high-pressure homogenizer 
(PANDA 2K, NiroSoavi, Italy) at 700 bar pressure and three cycles to form 
the NLC dispersion. Then, the formulated NLC was allowed to cool at room 
temperature which was further used for characterization [9,10].
Preparation of LXM loaded NLC gel
LXM loaded NLC gel was prepared using different gelling agents 
such as Carbopol-940 and xanthan gum. Based on the compatibility 
with nanoparticulate dispersion, feel esthetic appeal and ease of 
spreadability Carbopol 940 were selected as the gelling agent. Different 
concentrations of Carbopol 940 ranging from 0.50 to 1% were used 
for gelling, and the concentration giving the optimum viscosity (0.7%) 
was chosen for the formulation of gel. Carbopol 940 was added to the 
nanoparticle dispersion under mechanical stirring at 800 rpm. Stirring 
was continued until the Carbopol 940 got dispersed. The Carbopol 
dispersion was neutralized using 0.2 mL triethanolamine [11].
Evaluation and characterization
Particle size analysis was performed by photon correlation spectroscopy 
with a Malvern Zetasizer (Nano ZS 90, Malvern Ltd., UK). The NLCs were 
evaluated for the rheological behavior using Brookfield Viscometer 
(RVDV Pro II). Entrapment efficiency (EE) and drug loading could be 
achieved by the following equations [12,13].
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In vitro drug diffusion study
In vitro drug diffusion study was performed using the diffusion cell 
assembly. The drug-loaded NLC gel was evaluated using dialysis 
membrane (molecular weight cutoff > 12,000, HiMedia) as a barrier 
containing pH 7.4 phosphate buffer solution as a media at 371 nm 
wavelength [10-13].
Ex vivo skin irritation studies
The albino Wistar rats were divided into two groups with three rats in 
each group. On the previous day of the experiment, the hairs on the back 
side area of rats were removed. The animals of Group I were served as 
control, without any treatment. Other group of animals (Group II) was 
applied with prepared NLCs based gel. Gel was applied once a day for 
7 days, and the site was covered with a cotton bandage and observed for 
any sensitivity. Score of erythema is read and recorded as Score 0 for no 
erythema; Score 1 for mild erythema (barely perceptible- light pink); 
Score 2 for moderate erythema (dark pink); and Score3 for severe 
erythema (extreme redness) [14].
In vivo studies
In vivo study of the anti-inflammatory drug was conducted on adult male 
Wistar rats having a weight range between 130 and 150 g. The animals 
were divided into three groups, each group containing three animals. 
Group I received a topical saline application (control group), Group II 
received marketed diclofenac gel, and Group III received LXM-NLC gel. 
The volume of paw edema (ml) was measured for each animal using 
a digital plethysmometer 2.0 (V.J. Instrument, Nashik, India). The rats 
were marked on the left hind paw just beyond the tibia-tarsal junction, 
and every time the paw was dipped in the electrolyte fluid column up 
to a fixed mark to make constant paw volume. The tested preparations 
were applied to the left hind paws of rats for 30 min before the initiation 
of inflammation by carrageenan. The initial paw volume of the rats was 
measured just before carrageenan injection, and the increase in volume 
due to fluid displacement was noted from a digital display, followed 
by an injection of 0.1 ml of 1% (w/v) carrageenan solution in saline 
Table 1: Predicted optimum ranges for independent factors
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in subplantar region of left hind paws of the rats. Measurement of paw 
volumes was done after 1, 2, 3, 4, and 5 h [15,16]. The percent inhibition 
rate was calculated as follows:
 
% Inhinition of edema






Stability testing of the drug product is a part of drug discovery and 
ends with the commercial product, to assess the drug and formulation 
stability, stability studies were done. The stability study was carried out 
for the most satisfactory formulation. The optimized gel formulation 
was sealed in a glass vial and kept at 30 +2°C at 65 + 5% RH for 1 months 
and analyzed. At the 1 month ending, the samples were analyzed for the 
drug content, pH determination, viscosity, and in vitro diffusion study.
RESULTS AND DISCUSSION
Selection of lipids
Based on the screening of lipids, for the maximum solubility of the 
drug in Precirol was selected as solid lipid for the formulation of NLC’s 
and has property such as good flow property, non toxicity, approved 
regulatory status, and cost which also favors its choice as solid lipid, 
oleic acid was screened out as most suitable liquid lipid to be used in 
the LXM-NLCs and poloxamer 188 was selected as a surfactant phase 
for the formulation of NLCs.
Drug-excipients interaction study
The possible interaction between the drug and the ingredients used 
in the preparation of the NLC was studied by FTIR and DSC. All the 
characteristic peaks of the drug appeared in the spectra of the physical 
mixture at the same wavenumber indicating no modification or 
interaction between the drug and the polymer shown in Fig. 1.
The DSC heating and cooling curves were recorded as a plot of enthalpy 
(in mW) versus temperature. For the LXM, the melting process took place 
at 218.75°C with a maximum peak at 220.66°C and for bulk material of 
Precirol melting process took place at 52.93°C with a maximum peak 
at 59.93°C. No significant change in the position of peaks was observed 
after running the physical mixture (1:1) of drug and solid lipid. Thus, 
the physical incompatibility between the components was discarded.
In the DSC thermogram of lyophilized LXM-NLCs, a small endothermic 
peak was observed around at 58°C due to the lipid Precirol as seen in 
Fig. 2. The disappearance of the exothermic peak of LXM in the LXM–
NLCs powder suggests that the drug is completely encapsulated in the 
lipid matrix and converted to amorphous state from crystalline state.
Preparation of NLCs
LXM-NLCs were prepared using hot high-pressure homogenizer as 
it is the best method used in the scale up production (Muller et al., 
2000). Indeed, it has been reported that lipid nanoparticles stabilized 
with surfactant mixtures have lower particle sizes and higher storage 
stability compared to formulations with only one surfactant (Mehnert 
and Maeder, 2001). It was observed from the preliminary studies that 
500 bars of pressure are enough to produce nanoparticles having 
a particle size of 200–300 nm. While the number of cycles through 
high-pressure homogenization was fixed to four cycles, it was seen 
that by increasing the number of cycles there was an increase in the 
surface kinetic energy over the particles leading to aggregation of the 
nanoparticle causing an increase in particle size [13,14].
Optimization and validation of formulas for the preparation LXM-
NLCs
The compositions of different batches of LXM-NLC by 32 factorial 
design are summarized in Table 1. Table 2 showed the experimental 
results concerning the tested variables on drug encapsulation efficiency 
(EE) and mean diameter of particle size. The two dependent values 
ranged from 98.38% to 99.51% by weight and 138.2 to –236.3 nm. 
A mathematical relationship between factors and parameter was 
generated by response surface regression analysis using Design-
Expert® 8.0.1 software for all nine formulation. The ranges of response 
Y1 and Y2 were 138.2–236.3 nm and 98.38–99.51%, respectively.
Regression equations for fitted quadratic interactive model
Y1 = 148.37 + 18.50 X1 - 16.92 X2 + 3.05 X1 X2 + 44.10 X12 + 12.65 X22
 (4)
  Y2 = 94.61 + 3.31 X1 + 0.37 X2 (5)
It was observed that the best fitted models were quadratic for both 
particle size (Y1) and EE (Y2). Quadratic model is selected because 
it shows the interactive effect of all the independent variables on 
 Fig. 1: Infrared spectrum of the physical mixture of lornoxicam 
and Precirol
 Fig. 2: Differential scanning calorimetry thermogram of freeze-dried nanostructured lipid carrier formulation of lornoxicam
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responses that linear/non-linear model does not show. The values 
of R2, adjusted R2, predicted R2, standard deviation, and percentage 
coefficient of variation are given in Table 2 along with the regression 
equation generated for each response. The results of ANOVA in the 
dependent variables demonstrate that P significance value for mean 
particle size and EE was 0.0108 and 0.002, respectively, so that the 
model was significant for both the response variables.
Response surface plots analysis
The contour plot shows predicted particle size values at different levels 
of lipid concentration and surfactant concentration (Fig. 3a). It can be 
seen that the increase in lipid concentration increased mean particle 
size, whereas an increase in surfactant concentration decreased the 
mean particle size. The surface response curve also shows increased 
particle size with increasing amount of lipid concentration, whereas 
an increase in the amount of surfactant concentration, led to a little 
reduction in particle size. The contour plot shows predicted EE values 
at different levels of lipid concentration and surfactant concentration 
(Fig. 3b). It can be seen that increase in lipid concentration. Whereas 
increase in surfactant concentration. slightly increase in entrapment 
efficiency. The surface response curve also shows increased EE with an 
increasing amount of lipid concentration, whereas an increase in the 
amount of surfactant concentration, led to slightly increase in EE [15].
Particle size analysis and polydispersibility index (PDI)
The particle size of the NLCs suspension is a crucial factor because 
it determines the rate and extent of drug release as well as drug 
absorption. The smaller droplet size provides a larger interfacial 
surface area for drug absorption. In addition, the smaller droplet size 
permits a faster release rate. Furthermore, it has been reported that 
the smaller particle size of the emulsion droplets may lead to faster 
absorption and improve the bioavailability. Furthermore, PDI measures 
the width of particle size distribution. If PDI is lower than 0.1, it might 
be associated with high homogeneity in the particles, whereas high PDI 
values suggest a broad size distribution. The particle size and PDI of the 
designed batches are shown in Table 3.
Particle size analysis, PDI, and percent EE
LXM- NLCs prepared in this work using the high-pressure 
homogenization technique showed high EE values with an increase in 
the percentage oleic acid content. The percentage EE of the resulting 
NLCs is presented in Table 4. It was observed that the increase in oil 
content, the percentage of encapsulated drug increases because the 
drug shows more solubility in the liquid lipid than the solid lipid as the 
number of imperfections in the crystal lattice increases in the presence 
of liquid lipid as compared to solid lipid. The high EE values observed in 
this study indicate that the lipid and surfactant compositions employed 
are very adequate for LXM entrapment in NLCs [15,16].
Table 2: Summary of results of regression analysis for responses Y1 and Y2
Models R2 value Adjusted R2 Predicted R2 S.D CV%
Response (Y1) quadratic 0.9780 0.9414 0.7331 7.75 4.16
Response (Y2) quadratic 0.9436 0.9249 0.8601 0.81 0.86
Table 3: Particle size, PDI, and entrapment efficiency of formulated NLCs
Batch code Particle size (nm) Polydispersity index (PDI) Entrapment efficiency (%)
F1 207.0±2.51 0.298±0.054 98.64±1.45
F2 167.4±1.52 0.359±0.046 91.83±2.13
F3 147.5±3.05 0.399±0.032 94.45±2.54
F4 138.2±3.60 0.344±0.034 96.90±1.98
F5 214.9±2.10 0.471±0.026 99.21±1.76
F6 184.7±2.60 0.437±0.045 93.22±2.17
F7 201.0±2.64 0.485±0.047 92.11±3.11
F8 178.8±2.08 0.381±0.052 90.80±3.01
F9 236.3±3.04 0.288±0.044 97.31±1.65
PDI: Polydispersibility index, NLC: Nanostructured lipid carrier
Table 4: Data showing stability studies
Sr. No. Parameters Storage period (1 month)
Initial 30 + 2°C at 
65 + 5% RH
1 Drug content (%) 94.99 ± 1.35 93.10 ± 2.05
2 PH 7.2 ± 0.20 7.2 ± 0.15
3 Viscosity (cp) 11654 ± 108.55 11265 ± 110.05
4 In vitro diffusion study (%) 90.92 ± 1.96 89.25 ± 1.05
Mean ± standard deviation (n = 3)
Fig. 3: Response surface plot showing the effect of lipid concentration with respect to surfactant concentration over mean particle size (a) 
and entrapment efficiency (b)
ba
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Zeta-potential measurement
The zeta-potential of the optimized LXM-NLC was found to be −27.8. 
It possesses negative surface charges due to the negatively charged 
Precirol. In addition to Precirol, surfactant (poloxamer 188) was also 
negatively charged. It is currently admitted that zeta potentials under 
(−30) mV are optimum and <(−60) mV are required for full electrostatic 
stabilization.
Optimized batch (F4) selected for the formulation of gel. The percent 
drug content of gel formulation was found to be 94.99±1.35%. This 
showed that drug was uniformly distributed in the formulated gel with 
viscosity 11654±1.55cp, PH 7.2±0.20, spreadability 9.4±0.25 (g.cm/s.), 
drug content 94.99±1.35%, and gel strength 20±0.90 s.
Rheological measurements
The apparent viscosity values were measured for gel formulations 
using Brookfield viscometer with spindle no. 64 at 10–100 rpm and 
100–10 rpm. In the gel state, all the formulations were observed to 
be exhibiting the pseudoplastic flow. The characteristic concavity of 
the rheogram toward the shear rate axis indicates that developed 
formulation exhibited pseudoplastic flow. This pseudoplasticity results 
from a colloidal network structure that aligns itself in the direction 
of shear, thereby decreasing the viscosity as the shear rate increases 
showed in Fig. 4. NLC loaded gels showed that upcurve does not coincide 
with the down curve, meaning that the samples are non newtonian in 
nature showing thixotropic behavior, however, with lower structural 
breakdown [18].
In vitro drug diffusion studies
On the basis of percentage EE and particle size batch F4 were selected 
for in vitro drug diffusion study. The release profiles exhibited an 
inflection point, which indicated the gel formation in the donor 
compartment of the diffusion cell. The results showed that the formed 
gels had the ability to extend the release of LXM for the duration of about 
24 h. The cumulative percentage of drug diffused was observed for 24 h, 
the sample was analyzed in triplicate. In Fig. 4 shows the cumulative 
percentage of drug diffusion patterns of the formulation. The amount 
of the polymer and the lipid may retard the drug diffusion giving more 
prolonged release of the drug [17, 18 ]. In 24 h of the drug diffusion 
study, the effect of the amount of polymer used and particle size of the 
formulation showed a direct relation with cumulative percentage drug 
diffused. The percentage drug diffused in first 8 h for the formulation 
was calculated, and the maximum diffusion was observed (53.08%). 
The release was observed from LXM-NLC gel which showed sustained 
and steady release over the entire period of study.
The results obtained in in vitro release studies were plotted in 
different kinetic models. Regression coefficient (R2) values for zero-
order 0.885, first-order 0.958, Higuchi Model 0.960, and Korsmeyer–
Peppas Model 0.970. This indicated that the release data were best 
fitted with Korsmeyer–Peppas kinetic plot model because the value 
of R2 is greater in this model [18,19]. The drug release data from the 
LXM-NLC’s gel were fitted into Korsmeyer–Peppas model to find the 
release mechanism. Model fitting revealed that LXM-NLCs gel showed 
anomalous transport (non-Fickian) mechanism for the release of drug 
based on the “n” value (0.533, which is 0.5 < n < 1), whereas R2 was 
found to be 0.970.
Skin irritation study
Skin irritation studies carried out on albino Wistar rats revealed that 
the gel formulation shows no erythema, edema, or ulceration. It shows 
to be nonirritant [19]. Thus, this formulation was suitable for topical 
application resulted in selecting the gel for further tests.
In vivo study (anti-inflammatory activities)
The anti-inflammatory activity of the optimized formulation was 
evaluated by the carrageenan-induced hind paw inflammation method 
on Wistar rats. The percentage inhibition value of LXM-NLC gel was 
compared to diclofenac gel. The formulation gel not only decreased 
the inflammation by a larger magnitude but also sustained the effect 
for a prolonged period. Hence, the NLC-based gel formulation of LXM 
remained superior to the marketed product in its ability to suppress 
edema and sustained the anti-inflammatory activity [19].
The mean paw edema volume in rats before carrageenan induced was 
0.75 + 0.05 for control (Saline), 0.80±0.02 for standard (diclofenac gel), 
and 0.82±0.02 for test (LXM – NLC gel) and after carrageenan induced 
shown in Table 5.
Stability study
In the stability study, after every 30 days, samples were withdrawn and 
retested for viscosity (cps) and drug content. The formulation did not 
show any significant change in both parameters. It indicates that this 
formulation was able to retain its stability for up to 3 months. Stability 
data are shown in Table 4.
CONCLUSION
NLC-based gel of LXM formulated in two-step process; first preparation 
of NLC dispersion followed by addition of the gelling agent. NLC 
dispersion was formulated by high-pressure homogenization method. 
As compared with the other methods, it showed the advantages of 
higher drug loading capacity, higher drug encapsulation efficiency, 
and no need for an organic solvent. Formulation comprising 2% of 
lipid (60:40) and surfactant (1.50%) was confirmed as a optimized 
batch having minimum values for particle size (138.2+3.60 nm) with 
PDI value 0.344+0.034. The zeta-potential was found to be -27.8, 
indicating good physical stability. The optimized batch also shows good 





Standard (diclofenac gel) Test (LXM-NLC gel) Standard (diclofenac gel) (%) Test (LXM-NLC gel) (%)
After carrageenan induced Percent inhibition edema rate
1 1.37±0.15 0.92±0.01 0.87±0.03 32.84±0.03 36.49±0.02
2 1.57±0.03 1.03±0.77 0.95±0.01 34.39±0.12 39.49±0.01
3 1.82±0.01 1.14±0.14 1.09±0.02 37.36±0.03 40.10±0.05
4 1.89±0.12 1.16±0.07 1.05±0.14 38.62±0.01 44.44±0.10
5 1.94±0.02 1.12±0.15 1.02±0.02 42.26±0.05 47.42±0.15
All values represent mean±standard deviation (n=3) P<0.0001 (compared with control). LXM: Lornoxicam, NLC: Nanostructured lipid carrier
 Fig. 4: Rheological behavior of gel formulation (F4)
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percentage EE of 96.90+1.98. Topical NLCs based gel appeared to be an 
interesting approach to improve problems associated with oral delivery 
of LXM which having severe adverse effects.
The topical gel has suitable gel strength (20+0.90 s) so as to be 
administered easily and retained at skin without leakage after 
administration. Based on the results from the in vitro release study it 
was shown that the formed gels had the ability to extend the release 
of LXM for the duration of about 24 h and showing percentage drug 
release of 90.92+1.96 at the end of 24 h. Skin irritation studies carried 
out on albino Wistar rats revealed that the optimized gel formulation 
shows no erythema, edema, or ulceration. It shows to be nonirritant. 
Following application of gel in left hind paw in rats, formulation 
provided significant anti-inflammatory activity compared to a standard 
drug. The overall results of the present study clearly indicated 
promising potentials of NLC-based gel for delivering LXM topically over 
the conventional gel. From the stability study, it was observed that F4 
batch is stable and used for topical application.
It can be finally concluded that formulating LXM-NLC gel considered a 
promising topical anti-inflammatory system and can be effectively used 
in acute inflammation and pain associated with arthritis.
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